<DOC>
	<DOCNO>NCT00560781</DOCNO>
	<brief_summary>This study test therapeutic potential augment stable SSRI regimen neurosteroid pregnenolone reduce cognitive symptom PTSD symptom patient diagnose PTSD .</brief_summary>
	<brief_title>Targeting Cognition PTSD : Pregnenolone Augmentation SSRIs</brief_title>
	<detailed_description>See brief summary</detailed_description>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<criteria>1 . 1865 year age , ethnic group , either sex 2 . DSMIV diagnosis PTSD MINI ( see schedule event ) 3 . No change SSRI medication &gt; 4 week . 4 . No anticipated need alter psychotropic medication 10week duration study . 5 . Ability fully participate informed consent process , legal guardian able participate inform consent process . 1 . Unstable medical neurological illness , include seizure , CVA , prostate breast cancer 2 . Use oral contraceptive hormonal supplementation estrogen . 3 . Significant suicidal homicidal ideation . 4 . Concomitant medication medical condition address casebycase base determine exclusionary . 5 . Current DSMIV diagnosis bipolar disorder , schizophrenia psychotic disorder , cognitive disorder due general medical condition ; history substance dependence within last 3 month 6 . Female patient pregnant breastfeeding . 7 . Known allergy study medication . 8 . Drugs narrow therapeutic index ( e.g . thioridazine , mesoridazine , ziprasidone , clozapine , etc . ) exclude , suggest FDA ; patient take agent eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Pregnenolone</keyword>
	<keyword>Cognition</keyword>
</DOC>